KT-001 is a novel ionizable cationic lipid developed by Vivas, Inc., disclosed in US 2026/0007612 A1 (published Jan 8, 2026).KT-001 demonstrates exceptional skeletal muscle targeting and low liver toxicity.Unlike traditional lipids that primarily accumulate in the liver, KT-001 avoids serum ApoE binding, preventing hepatic uptake. Upon intramuscular injection, it achieves a 29-fold reduction in liver off-target expression compared to standard lipids, while maintaining robust, long-lasting protein expression at the injection site.Its optimized pKa enables precise, pH-responsive endosomal escape for high transfection efficiency. KT-001 is an ideal carrier for localized mRNA vaccines and targeted therapeutics for muscle-related disorders.
